艾美汀
药物重新定位
腺癌
冠状病毒
生物
小桶
基因
生物信息学
转录组
计算生物学
疾病
药理学
医学
药品
2019年冠状病毒病(COVID-19)
内科学
遗传学
癌症
传染病(医学专业)
基因表达
作者
Kun Zhang,Ke Wang,Chaoguo Zhang,Xiuli Teng,Dan Li,Mingwei Chen
出处
期刊:BMC Cancer
[BioMed Central]
日期:2022-06-22
卷期号:22 (1): 687-687
被引量:11
标识
DOI:10.1186/s12885-022-09763-2
摘要
Abstract Background Patients with lung adenocarcinoma (LUAD) may be more predisposed to coronavirus disease 2019 (COVID-19) and have a poorer prognosis. Currently, there is still a lack of effective anti-LUAD/COVID-19 drugs. Thus, this study aimed to screen for an effective anti-LUAD/COVID-19 drug and explore the potential mechanisms. Methods Firstly, we performed differentially expressed gene (DEG) analysis on LUAD transcriptome profiling data in The Cancer Genome Atlas (TCGA), where intersections with COVID-19-related genes were screened out. Then, we conducted Cox proportional hazards analyses on these LUAD/COVID-19 DEGs to construct a risk score. Next, LUAD/COVID-19 DEGs were uploaded on Connectivity Map to obtain drugs for anti-LUAD/COVID-19. Finally, we used network pharmacology, molecular docking, and molecular dynamics (MD) simulation to explore the drug’s therapeutic targets and potential mechanisms for anti-LUAD/COVID-19. Results We identified 230 LUAD/COVID-19 DEGs and constructed a risk score containing 7 genes ( BTK , CCL20 , FURIN , LDHA , TRPA1 , ZIC5 , and SDK1 ) that could classify LUAD patients into two risk groups. Then, we screened emetine as an effective drug for anti-LUAD/COVID-19. Network pharmacology analyses identified 6 potential targets ( IL6 , DPP4 , MIF , PRF1 , SERPING1 , and SLC6A4 ) for emetine in anti-LUAD/COVID-19. Molecular docking and MD simulation analyses showed that emetine exhibited excellent binding capacities to DDP4 and the main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Conclusions This study found that emetine may inhibit the entry and replication of SARS-CoV-2 and enhance tumor immunity by bounding to DDP4 and Mpro.
科研通智能强力驱动
Strongly Powered by AbleSci AI